Design Therapeutics (DSGN) investor relations material

Company overview and business model

• Clinical-stage biopharma developing GeneTAC® small molecules designed to target inherited nucleotide repeat expansions and modulate gene expression to address underlying disease causes.

• Candidate applications include Friedreich ataxia, fragile X syndrome, DM1, FECD and Huntington’s disease; the platform is described as potentially applicable to repeat-expansion diseases affecting millions worldwide.

Use of proceeds and capital allocation

• Net proceeds are intended for general corporate purposes, including R&D, clinical trials, capital expenditures and G&A; potential licensing, investment or acquisitions may also be considered.

• No acquisition plans, commitments or agreements are current; proceeds may be held in short- and intermediate-term interest-bearing obligations, investment-grade instruments, CDs or U.S. government obligations pending use.

Risk factors and disclosures

• Investment carries a high degree of risk; disclosed risks and additional unknown or currently immaterial risks could adversely affect operations, financial condition and security value, including causing a total or partial investment loss.

• Forward-looking statements cover strategy, R&D, trials, regulatory outcomes, commercialization and market growth; actual results may differ materially, and there is generally no obligation to update statements.

• Board-authorized preferred stock could dilute common voting rights or impede a change of control; classified-board and other charter provisions may delay or deter takeovers and management changes.

• Debt securities may carry limited protections against operating or financial changes; global-security investors may hold indirect interests and depend on intermediaries for payments, notices and rights enforcement.